- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07838324
A Pilot Investigation of Pain Reprocessing Therapy for Functional Dyspepsia
The purpose of this research is to test whether pain processing therapy, a novel psychological intervention that emphasizes exposure-based techniques, can reduce digestive symptom severity and improve functioning in people with functional dyspepsia.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Typ studiów
Zapisy (Szacowany)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Jonah Pedelty
- Numer telefonu: 507-538-7774
- E-mail: Pedelty.Jonah@mayo.edu
Lokalizacje studiów
-
-
Minnesota
-
Rochester, Minnesota, Stany Zjednoczone, 55905
- Rekrutacyjny
- Mayo Clinic
-
Kontakt:
- Jonah Pedelty
- Numer telefonu: 507-538-7774
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Fulfilled Rome V diagnostic criteria for functional dyspepsia postprandial distress syndrome subtype, with or without epigastric pain syndrome.
- A total score of at least 3 on the Gastroparesis Cardinal Symptom Index (GCSI) indicating symptom severity to be moderate or higher.
- Normal gastric emptying as confirmed by standard gastric emptying testing (if such a testing was clinically done).
- Upper endoscopy negative to rule out structural or organic etiologies for GI symptoms (within last 1 year).
- Fluent in English language.
- Able to provide informed consent and comply with study procedures.
Exclusion Criteria:
- Evidence of organic gastrointestinal disease or surgical history that could explain participant symptoms (e.g., peptic ulcer disease, celiac disease, inflammatory bowel disease, eosinophilic gastritis or eosinophilic esophagitis, malignancy).
- Current or recent (within the past 12 months) eating disorder such as anorexia nervosa or bulimia nervosa. Historical eating disorder diagnosis may also be exclusionary if residual disordered eating patterns, fear of weight gain, or food-related body image concerns are judged by the investigator to potentially confound symptom interpretation or participation.
- Underweight BMI (<17 kg/m²) or evidence of clinically significant unintentional weight loss (>25% body weight in 6 months).
- Current use of enteral or parenteral nutrition for >50% of caloric needs and/or participant unwillingness to reduce use of enteral or parenteral nutrition at the time of study enrollment.
- History of developmental or intellectual disability, current cognitive impairment that would preclude participation, or other neurological illness impairing cognitive functioning.
- Active suicidal ideation, suicide attempt within the past 12 months, severe psychiatric illness, severe depressive symptomatology, acute distress, or other symptomatology that, in the investigator's judgment, would necessitate a different level of psychiatric care and/or prevent full engagement in psychological intervention sessions or adherence to study procedures.
- Medical disability or any unstable systemic illness (e.g., decompensated hepatic, cardiac, renal, or neurological disease) that could interfere with participation, comprehension, or safety in psychological intervention sessions.
- Current daily cannabis use (inhaled, edible, or medical). Other substance use or misuse of prescription medications may also be exclusionary if substance use patterns are judged by the investigator to potentially confound symptom interpretation or participation.
- Current pregnancy or lactation.
- Inability or unwillingness of individual to give informed consent.
- Non-fluent in English, or any condition that would limit compliance or follow-up.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nie dotyczy
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Pain Reprocessing Therapy
Participants will receive eight weekly pain reprocessing therapy sessions. Session 1 will occur at Week 0, and sessions will continue weekly through Session 8 at Week 7. The first and last sessions will be delivered in person when possible to coordinate with baseline and post-treatment physiologic testing, and interim sessions will be completed via telehealth. |
Pain reprocessing therapy is a psychological intervention designed to help patients reconceptualize chronic symptoms in functional dyspepsia as related to changes in brain-gut communication. Treatment includes education about the neuroscience of chronic symptoms, development of a personalized understanding of symptom mechanisms, interoceptive exposure using mindfulness and safety reappraisal, approaches to reduce symptom-related fear and avoidance, techniques for addressing psychosocial threat factors, and strategies to increase positive emotional experiences. |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change in Average Gastroparesis Cardinal Symptom Index Score
Ramy czasowe: Baseline, Week 7
|
Change in average Gastroparesis Cardinal Symptom Index score from the Patient Assessment of Upper Gastrointestinal Disorders Symptoms Questionnaire will be assessed. The Gastroparesis Cardinal Symptom Index assesses upper gastrointestinal symptom severity; higher scores indicate greater symptom severity. |
Baseline, Week 7
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change in Maximum Tolerated Volume During Nutrient Drink Test
Ramy czasowe: Baseline, Week 7
|
Change in maximum tolerated volume consumed during the nutrient drink test will be assessed. Maximum tolerated volume is the total volume of nutrient drink consumed before the participant reaches the protocol-defined stopping point. |
Baseline, Week 7
|
|
Change in Symptom Ratings During Nutrient Drink Test
Ramy czasowe: Baseline, Week 7
|
Change in standardized symptom ratings collected during the nutrient drink test will be assessed. Symptoms may include fullness, nausea, bloating, and abdominal pain, with higher scores indicating greater symptom severity. |
Baseline, Week 7
|
|
Change in Patient Assessment of Upper Gastrointestinal Disorders-Quality of Life Score
Ramy czasowe: Baseline, Week 7
|
Change in Patient Assessment of Upper Gastrointestinal Disorders-Quality of Life score will be assessed. The questionnaire measures disease-specific quality of life in participants with upper gastrointestinal disorders; higher scores indicate better quality of life. |
Baseline, Week 7
|
|
Mean Change From Baseline in Gastrointestinal Unhelpful Thinking Scale Pain Catastrophizing Subscale Score
Ramy czasowe: Baseline, Week 7
|
Gastrointestinal-specific pain catastrophizing will be assessed using the Pain Catastrophizing subscale of the Gastrointestinal Unhelpful Thinking Scale. Mean scores will be calculated at baseline and following completion of treatment. A negative change from baseline indicates improvement in gastrointestinal-specific pain catastrophizing. |
Baseline, Week 7
|
|
Mean Change From Baseline in Visceral Sensitivity Index Score
Ramy czasowe: Baseline, Week 7
|
Gastrointestinal-specific anxiety will be assessed using the Visceral Sensitivity Index. Mean scores will be calculated at baseline and following completion of treatment. A negative change from baseline indicates improvement in gastrointestinal-specific anxiety. |
Baseline, Week 7
|
|
Mean Change From Baseline in Fear of Food Questionnaire Score
Ramy czasowe: Baseline, Week 7
|
Food-related fear and avoidance will be assessed using the Fear of Food Questionnaire. Mean scores will be calculated at baseline and following completion of treatment. A negative change from baseline indicates improvement in food-related fear and avoidance. |
Baseline, Week 7
|
|
Mean Change From Baseline in Nine Item ARFID Screen Fear Subscale Score
Ramy czasowe: Baseline, Week 7
|
Restrictive eating behaviors related to fear of aversive consequences will be assessed using the fear subscale of the Nine Item ARFID Screen. Mean scores will be calculated at baseline and following completion of treatment. A negative change from baseline indicates improvement in fear-related restrictive eating behaviors. |
Baseline, Week 7
|
|
Mean Change From Baseline in PROMIS Physical Function Score
Ramy czasowe: Baseline, Week 7
|
General physical function will be assessed using the PROMIS Physical Function scale. Mean scores will be calculated at baseline and following completion of treatment. A positive change from baseline indicates improvement in physical function. |
Baseline, Week 7
|
|
Mean Change From Baseline in PROMIS Anxiety Score
Ramy czasowe: Baseline, Week 7
|
Anxiety will be assessed using the PROMIS Anxiety scale. Mean scores will be calculated at baseline and following completion of treatment. A negative change from baseline indicates improvement in anxiety. |
Baseline, Week 7
|
|
Mean Change From Baseline in PROMIS Depression Score
Ramy czasowe: Baseline, Week 7
|
Depression will be assessed using the PROMIS Depression scale. Mean scores will be calculated at baseline and following completion of treatment. A negative change from baseline indicates improvement in depression. |
Baseline, Week 7
|
|
Mean Change From Baseline in PROMIS Fatigue Score
Ramy czasowe: Baseline, Week 7
|
Fatigue will be assessed using the PROMIS Fatigue scale. Mean scores will be calculated at baseline and following completion of treatment. A negative change from baseline indicates improvement in fatigue. |
Baseline, Week 7
|
|
Mean Change From Baseline in PROMIS Sleep Disturbance Score
Ramy czasowe: Baseline, Week 7
|
Sleep disturbance will be assessed using the PROMIS Sleep Disturbance scale. Mean scores will be calculated at baseline and following completion of treatment. A negative change from baseline indicates improvement in sleep disturbance. |
Baseline, Week 7
|
|
Mean Change From Baseline in PROMIS Ability to Participate in Social Roles and Activities Score
Ramy czasowe: Baseline, Week 7
|
Ability to participate in social roles and activities will be assessed using the PROMIS Ability to Participate in Social Roles and Activities scale. Mean scores will be calculated at baseline and following completion of treatment. A positive change from baseline indicates improvement in social participation. |
Baseline, Week 7
|
|
Mean Change From Baseline in PROMIS Pain Interference Score
Ramy czasowe: Baseline, Week 7
|
Pain interference will be assessed using the PROMIS Pain Interference scale. Mean scores will be calculated at baseline and following completion of treatment. A negative change from baseline indicates improvement in pain interference. |
Baseline, Week 7
|
|
Mean Change From Baseline in PROMIS Pain Intensity Score
Ramy czasowe: Baseline, Week 7
|
Pain intensity will be assessed using the PROMIS Pain Intensity numerical rating scale. Mean scores will be calculated at baseline and following completion of treatment. A negative change from baseline indicates improvement in pain intensity. |
Baseline, Week 7
|
|
Mean Change From Baseline in PROMIS Anger Score
Ramy czasowe: Baseline, Week 7
|
Anger will be assessed using the PROMIS Anger scale. Mean scores will be calculated at baseline and following completion of treatment. A negative change from baseline indicates improvement in anger. |
Baseline, Week 7
|
|
Percentage of Participants Who Complete the Pain Reprocessing Therapy Intervention
Ramy czasowe: Baseline, Week 7
|
The percentage of enrolled participants who complete all 8 planned pain reprocessing therapy sessions will be reported. |
Baseline, Week 7
|
|
Percentage of Participants Who Report Satisfaction With Pain Reprocessing Therapy
Ramy czasowe: Week 7
|
The percentage of participants who rate satisfaction with services as "mostly satisfied" or "very satisfied" on the Client Satisfaction Questionnaire-4 will be reported. |
Week 7
|
Współpracownicy i badacze
Sponsor
Śledczy
- Główny śledczy: Megan Petrick, PhD, Mayo Clinic
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Inne numery identyfikacyjne badania
- 26-003631
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .